PMID- 33787394
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20220122
IS  - 2150-1327 (Electronic)
IS  - 2150-1319 (Print)
IS  - 2150-1319 (Linking)
VI  - 12
DP  - 2021 Jan-Dec
TI  - Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events 
      in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 
      2018.
PG  - 21501327211007015
LID - 10.1177/21501327211007015 [doi]
LID - 21501327211007015
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) greatly increases cardiovascular 
      risk. Primary and secondary cardiovascular prevention lead to lower 
      cardiovascular events, improved quality of life and lower costs related to 
      complications. OBJECTIVE: To estimate the proportion of patients with T2DM 
      undergoing drug therapy for cardiovascular prevention (aspirin and statins) in 
      Colombia and to describe the change in patterns of use between 2008 and 2018. 
      METHODS: This was a cross-sectional study comparing prescriptions for aspirin and 
      statins in 2008 and in 2018 in outpatients diagnosed with T2DM. Records were 
      obtained from a national drug claim database. The proportion of use of 
      cardiovascular prevention drugs and antidiabetic drugs, medications for 
      comorbidities and sociodemographic variables were analyzed for both periods. 
      RESULTS: In total, 26 742 patients in 2008 and 188 321 in 2018 with a diagnosis 
      of T2DM treated with antidiabetic drugs were identified, among whom 57.5% and 
      44.2% received aspirin and 44.9% and 60.2% received statins, respectively. The 
      use of high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018. The 
      probabilities of receiving drugs in 2008 and in 2018 were higher for men (OR: 
      1.12, 95% CI: 1.06-1.17 and OR: 1.26, 95% CI: 1.23-1.28, respectively), for those 
      persons over 75 years of age (OR: 6.5, 95% CI: 5.3-7.9 and OR: 5.8, 95% CI: 
      5.4-6.2) and for those who also received clopidogrel (OR: 5.8, 95% CI: 4.4-7.6 
      and OR: 2.2, 95% CI: 2.1-2.4). CONCLUSIONS: The use of high-intensity statins in 
      patients with T2DM has increased significantly in the last decade, which should 
      reduce cardiovascular events, morbidity and mortality.
FAU - Machado-Duque, Manuel E
AU  - Machado-Duque ME
AD  - Universidad Tecnologica de Pereira-Audifarma S.A., Pereira, Colombia.
AD  - Fundacion Universitaria Autonoma de las Americas, Pereira, Colombia.
FAU - Garcia, Diego Arturo
AU  - Garcia DA
AD  - Fundacion Universitaria Autonoma de las Americas, Pereira, Colombia.
FAU - Emura-Velez, Melissa Hiromi
AU  - Emura-Velez MH
AD  - Fundacion Universitaria Autonoma de las Americas, Pereira, Colombia.
FAU - Gaviria-Mendoza, Andres
AU  - Gaviria-Mendoza A
AD  - Universidad Tecnologica de Pereira-Audifarma S.A., Pereira, Colombia.
AD  - Fundacion Universitaria Autonoma de las Americas, Pereira, Colombia.
FAU - Machado-Alba, Jorge E
AU  - Machado-Alba JE
AUID- ORCID: 0000-0002-8455-0936
AD  - Universidad Tecnologica de Pereira-Audifarma S.A., Pereira, Colombia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Prim Care Community Health
JT  - Journal of primary care & community health
JID - 101518419
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pharmaceutical Preparations)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - *Cardiovascular Diseases/epidemiology/prevention & control
MH  - Colombia/epidemiology
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Humans
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Male
MH  - *Pharmaceutical Preparations
MH  - Prevalence
MH  - Quality of Life
PMC - PMC8772352
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - aspirin
OT  - cardiovascular diseases
OT  - hydroxymethylglutaryl-CoA reductase inhibitors
OT  - hypolipidemic agents
OT  - pharmacoepidemiology
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/04/01 06:00
MHDA- 2021/06/25 06:00
PMCR- 2021/03/31
CRDT- 2021/03/31 13:01
PHST- 2021/03/31 13:01 [entrez]
PHST- 2021/04/01 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2021/03/31 00:00 [pmc-release]
AID - 10.1177_21501327211007015 [pii]
AID - 10.1177/21501327211007015 [doi]
PST - ppublish
SO  - J Prim Care Community Health. 2021 Jan-Dec;12:21501327211007015. doi: 
      10.1177/21501327211007015.